Federated Hermes, Inc. Cti Biopharma Corp Transaction History

Federated Hermes, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$5.36 - $7.43 $1,002 - $1,389	-187 Reduced 99.47%	1 $1,000
Q2 2022 Aug 15, 2022	BUY	$3.55 - $6.27 $667 - $1,178	188 New	188 $1,000
Q3 2020 Nov 12, 2020	SELL	$1.02 - $2.15 $213 - $449	-209 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$0.88 - $1.32 $403 - $604	-458 Reduced 68.67%	209 $1,000
Q3 2019 Nov 14, 2019	SELL	$0.64 - $0.92 $860 - $1,236	-1,344 Reduced 66.83%	667 $1,000
Q3 2018 Nov 13, 2018	SELL	$1.72 - $5.24 $749 - $2,284	-436 Reduced 17.82%	2,011 $4,000
Q2 2018 Aug 10, 2018	BUY	$3.81 - $5.26 $4,507 - $6,222	1,183 Added 93.59%	2,447 $12,000
Q1 2018 May 09, 2018	BUY	$2.7 - $4.06 $3,412 - $5,131	1,264 New	1,264 $5,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.